Étude du trafic cellulaire de la convertase de proprotéine PCSK9 responsable de la dégradation du récepteur des lipoprotéines de faible densité (LDLR)

Les maladies cardiovasculaires (MCV) sont la principale cause de mortalité dans les pays industrialisés. L'hypercholestérolémie constitue un facteur de risque majeur pour les MCV. Elle est caractérisée par des niveaux élevés de lipoprotéines de faible densité (LDL, aussi appelé “mauvais cholestérol”). La présence prolongée de haut niveaux de LDL dans la circulation augmente le risque de formation de plaques athérosclérotiques, ce qui peut conduire à l'obstruction des artères et l'infarctus du myocarde. Le LDL est normalement extrait du sang par sa liaison au récepteur du LDL (LDLR) qui est responsable de son endocytose dans les hépatocytes. Des études génétiques humaines ont identifié PCSK9 (proprotein convertase subtilisin/kexin type 9) comme le troisième locus responsable de l'hypercholestérolémie autosomique dominante après le LDLR et son ligand l’apolipoprotéine B-100. PCSK9 interagit avec le LDLR et induit sa dégradation, augmentant ainsi les niveaux plasmatiques de LDL. Les mutations gain de fonction (GF) de PCSK9 sont associées à des niveaux plasmatiques élevés de LDL et à l'apparition précoce des MCV, alors que les mutations perte de fonction (PF) de PCSK9 diminuent le risque de MCV jusqu’à ~ 88% grâce à une réduction du LDL circulant. De ce fait, PCSK9 constitue une cible pharmacologique importante pour réduire le risque de MCV. PCSK9 lie le LDLR à la surface cellulaire et/ou dans l'appareil de Golgi des hépatocytes et provoque sa dégradation dans les lysosomes par un mécanisme encore mal compris. Le but de cette étude est de déterminer pourquoi certaines mutations humaines de PCSK9 sont incapables de dégrader le LDLR tandis que d'autres augmentent sa dégradation dans les lysosomes. Plusieurs mutations GF et PF de PCSK9 ont été fusionnées à la protéine fluorecente mCherry dans le but d'étudier leur mobilité moléculaire dans les cellules hépatiques vivantes. Nos analyses quantitatives de recouvrement de fluorescence après photoblanchiment (FRAP) ont montré que les mutations GF (S127R et D129G) avaient une mobilité protéique plus élevée (> 35% par rapport au WT) dans le réseau trans- Golgien. En outre, nos analyses quantitatives de recouvrement de fluorescence inverse après photoblanchiment (iFRAP) ont montré que les mutations PF de PCSK9 (R46L) avaient une mobilité protéique plus lente (<22% par rapport au WT) et une fraction mobile beaucoup plus petite (<40% par rapport au WT). Par ailleurs, nos analyses de microscopie confocale et électronique démontrent pour la toute première fois que PCSK9 est localisée et concentrée dans le TGN des hépatocytes humains via son domaine Cterminal (CHRD) qui est essentiel à la dégradation du LDLR. De plus, nos analyses sur des cellules vivantes démontrent pour la première fois que le CHRD n'est pas nécessaire à l'internalisation de PCSK9. Ces résultats apportent de nouveaux éléments importants sur le mécanisme d'action de PCSK9 et pourront contribuer ultimement au développement d'inhibiteurs de la dégradation du LDLR induite par PCSK9.

Développement d'une sonde fluorescente bioactivable pour l'étude du rôle in vitro et in vivo des protéases dégradant l’apolipoprotéine A-I.

Les effets bénéfiques des lipoprotéines de haute densité (HDL) contre l'athérosclérose ont été attribués, en grande partie, à leur composante protéique majeure, l'apolipoprotéine A-I (apoA-I). Cependant, il y a des indications que l'apoA-I peut être dégradée par des protéases localisées dans les plaques athérosclérotiques humaines, ce qui pourrait réduire l'efficacité des thérapies basées sur les HDL sous certaines conditions. Nous décrivons ici le développement et l'utilisation d'une nouvelle sonde bioactivatable fluorescente dans le proche infrarouge, apoA-I-Cy5.5, pour l'évaluation des activités protéolytiques spécifiques qui dégradent l'apoA-I in vitro, in vivo et ex vivo. La fluorescence basale de la sonde est inhibée par la saturation du fluorophore Cy5.5 sur la protéine apoA-I, et la fluorescence émise par le Cy5.5 (proche infrarouge) est révélée après clivage de la sonde. La protéolyse in vitro de l'apoA-I par des protéases a montré une augmentation de la fluorescence allant jusqu'à 11 fois (n=5, P ≤ 0.05). En utilisant notre nouvelle sonde apoA-I-Cy5.5 nous avons pu quantifier les activités protéolytiques d'une grande variété de protéases, incluant des sérines (chymase), des cystéines (cathepsine S), et des métalloprotéases (MMP-12). En outre, nous avons pu détecter l'activation de la sonde apoA-I-Cy5.5 sur des sections d'aorte de souris athérosclérotiques par zymographie in situ et avons observé qu'en présence d'inhibiteurs de protéases à large spectre, la sonde pourrait être protégée des activités protéolytiques des protéases (-54%, n=6, P ≤ 0,001). L'infusion in vivo de la sonde apoA-I-Cy5.5 dans les souris athérosclérotiques (Ldlr -/--Tg (apoB humaine)) a résulté en utilisant un système d'imagerie moléculaire combinant la fluorescence moléculaire tomographique et la résonance magnétique,en un signal de fluorescence dans l'aorte plus important que celui dans les aortes des souris de type sauvage C57Bl/6J (CTL). Les mesures in vivo ont été confirmées par l'imagerie ex vivo de l'aorte qui a indiqué une augmentation de 5 fois du signal fluorescent dans l'aorte des souris ATX (n=5) par rapport à l'aorte des souris (n=3) CTL (P ≤ 0,05). L'utilisation de cette sonde pourrait conduire à une meilleure compréhension des mécanismes moléculaires qui sous-tendent le développement et la progression de l'athérosclérose et l'amélioration des stratégies thérapeutiques à base de HDL.

Gu??a de participaci??n en los centros docentes

T??t. tomado de la cub. Contiene: Gu??a de participaci??n en centros docentes. - 66 p. ; Experiencias de participaci??n I. - 31 p. ; Experiencias de participaci??n II. - 39 p. ; Gu??a para asesorar sobre participaci??n de las familias, constituci??n y funcionamiento de la AMPAS. - 47 p. ; Los Consejos Escolares de los centros docentes. - 10 p. ; Gu??a para asesorar sobre participaci??n del alumnado, constituci??n y funcionamiento de las asociaciones de alumnos y alumnas. - 27 p.

Factores de riesgo cardiovascular en hermanos de pacientes con enfermedad coronaria temprana y severa

La enfermedad coronaria es la principal causa de mortalidad global. A pesar de la intervención sobre los factores de riesgo las tasas de incidencia de eventos cardiovasculares continúan siendo altas. Se han identificado nuevos factores denominados “no-tradicionales” los cuales estarían presentes temprano en la enfermedad cardiovascular. Objetivo: Demostrar factores de riesgo tradicionales y no-tradicionales hermanos de pacientes con enfermedad coronaria temprana. Metodología: Estudio transversal (n=94), se excluyeron 10 por no cumplir con los criterios de inclusión. Se dividieron en 4 grupos cada uno de 21 sujetos según el caso índice. Diagnosticados con enfermedad coronaria severa por coronariografía. Dividiendo los grupos según la edad de diagnóstico, menores y mayores de 50 años, luego tomando a uno de sus hermanos de cualquier sexo. Resultados: Los niveles de Apolipoproteína A (p 0.001 y 0.003) y HDL (p <0.001 y 0.007) son menores en los pacientes (menores y mayores de 50 años) con un evento coronario agudo que en sus hermanos. La hsCRP no mostró diferencias estadísticamente significativas en los diferentes grupos, pero se observaron mayores niveles de esta a mayor extensión de la enfermedad coronaria. Conclusiones: Los niveles de Apolipoproteina A son menores en pacientes con evento coronaria agudo que en sus hermanos; la hsCRP se correlaciona con mayor extensión de la enfermedad coronaria. Se necesitan más estudios para evaluar si los resultados son reproducibles y proporcionar más pruebas sobre el tema con el fin de formalizar esta práctica. Palabras clave: Enfermedad coronaria, Técnicas de Diagnóstico Cardiovascular, Proteína C-Reactiva, Apolipoproteína A-I

Polimorfismos del gen Butirilcolinesterasa responsables de reacciones adversas en pacientes consumidores de “cocaína”

La butirilcolinesterasa humana (BChE; EC 3.1.1.8) es una enzima polimórfica sintetizada en el hígado y en el tejido adiposo, ampliamente distribuida en el organismo y encargada de hidrolizar algunos ésteres de colina como la procaína, ésteres alifáticos como el ácido acetilsalicílico, fármacos como la metilprednisolona, el mivacurium y la succinilcolina y drogas de uso y/o abuso como la heroína y la cocaína. Es codificada por el gen BCHE (OMIM 177400), habiéndose identificado más de 100 variantes, algunas no estudiadas plenamente, además de la forma más frecuente, llamada usual o silvestre. Diferentes polimorfismos del gen BCHE se han relacionado con la síntesis de enzimas con niveles variados de actividad catalítica. Las bases moleculares de algunas de esas variantes genéticas han sido reportadas, entre las que se encuentra las variantes Atípica (A), fluoruro-resistente del tipo 1 y 2 (F-1 y F-2), silente (S), Kalow (K), James (J) y Hammersmith (H). En este estudio, en un grupo de pacientes se aplicó el instrumento validado Lifetime Severity Index for Cocaine Use Disorder (LSI-C) para evaluar la gravedad del consumo de “cocaína” a lo largo de la vida. Además, se determinaron Polimorfismos de Nucleótido Simple (SNPs) en el gen BCHE conocidos como responsables de reacciones adversas en pacientes consumidores de “cocaína” mediante secuenciación del gen y se predijo el efecto delos SNPs sobre la función y la estructura de la proteína, mediante el uso de herramientas bio-informáticas. El instrumento LSI-C ofreció resultados en cuatro dimensiones: consumo a lo largo de la vida, consumo reciente, dependencia psicológica e intento de abandono del consumo. Los estudios de análisis molecular permitieron observar dos SNPs codificantes (cSNPs) no sinónimos en el 27.3% de la muestra, c.293A>G (p.Asp98Gly) y c.1699G>A (p.Ala567Thr), localizados en los exones 2 y 4, que corresponden, desde el punto de vista funcional, a la variante Atípica (A) [dbSNP: rs1799807] y a la variante Kalow (K) [dbSNP: rs1803274] de la enzima BChE, respectivamente. Los estudios de predicción In silico establecieron para el SNP p.Asp98Gly un carácter patogénico, mientras que para el SNP p.Ala567Thr, mostraron un comportamiento neutro. El análisis de los resultados permite proponer la existencia de una relación entre polimorfismos o variantes genéticas responsables de una baja actividad catalítica y/o baja concentración plasmática de la enzima BChE y algunas de las reacciones adversas ocurridas en pacientes consumidores de cocaína.

Triacylglycerol-rich lipoprotein-gene interactions in endothelial cells

Lipoproteins such as LDL (low-density lipoprotein) and oxidized LDL have potentially adverse effects on endothelial cells due to their ability to activate pro-inflammatory pathways regulated via the transcription factor NF-kappaB (nuclear factor kappaB). Triacylglycerol-rich lipoproteins (the chylomicrons, very-low-density lipoprotein and their respective remnant particles) have also been implicated in the induction of a pro-inflammatory phenotype and up-regulation of adhesion molecule expression. Although early studies supported the proposal that LPL (lipoprotein lipase)-mediated hydrolysis of TRLs (triglyceride-rich lipoproteins) at the endothelium could activate the NFkappaB pathway, more recent studies provide evidence of pro-and anti-inflammatory responses when cells are exposed to fatty acids of TRL particles. A large number of genes are up- and down-regulated when cells are exposed to TRL, with the net effect reflecting receptor- and nonreceptor-mediated pathways that are activated or inhibited depending on fatty acid type, the lipid and apolipoprotein composition of the TRL and the presence or absence of LPL. Early concepts of TRL particles as essentially pro-inflammatory stimuli to the endothelium provide an overly simplistic view of their impact on the vascular compartment.

A continuum receptor model of hepatic lipoprotein metabolism

A mathematical model describing the uptake of low density lipoprotein (LDL) and very low density lipoprotein (VLDL) particles by a single hepatocyte cell is formulated and solved. The model includes a description of the dynamic change in receptor density on the surface of the cell due to the binding and dissociation of the lipoprotein particles, the subsequent internalisation of bound particles, receptors and unbound receptors, the recycling of receptors to the cell surface, cholesterol dependent de novo receptor formation by the cell and the effect that particle uptake has on the cell's overall cholesterol content. The effect that blocking access to LDL receptors by VLDL, or internalisation of VLDL particles containing different amounts of apolipoprotein E (we will refer to these particles as VLDL-2 and VLDL-3) has on LDL uptake is explored. By comparison with experimental data we find that measures of cell cholesterol content are important in differentiating between the mechanisms by which VLDL is thought to inhibit LDL uptake. We extend our work to show that in the presence of both types of VLDL particle (VLDL-2 and VLDL-3), measuring relative LDL uptake does not allow differentiation between the results of blocking and internalisation of each VLDL particle to be made. Instead by considering the intracellular cholesterol content it is found that internalisation of VLDL-2 and VLDL-3 leads to the highest intracellular cholesterol concentration. A sensitivity analysis of the model reveals that binding, unbinding and internalisation rates, the fraction of receptors recycled and the rate at which the cholesterol dependent free receptors are created by the cell have important implications for the overall uptake dynamics of either VLDL or LDL particles and subsequent intracellular cholesterol concentration. (C) 2008 Elsevier Ltd. All rights reserved.

Mathematical model for low density lipoprotein (LDL) endocytosis by hepatocytes

Individuals with elevated levels of plasma low density lipoprotein (LDL) cholesterol (LDL-C) are considered to be at risk of developing coronary heart disease. LDL particles are removed from the blood by a process known as receptor-mediated endocytosis, which occurs mainly in the liver. A series of classical experiments delineated the major steps in the endocytotic process; apolipoprotein B-100 present on LDL particles binds to a specific receptor (LDL receptor, LDL-R) in specialized areas of the cell surface called clathrin-coated pits. The pit comprising the LDL-LDL-R complex is internalized forming a cytoplasmic endosome. Fusion of the endosome with a lysosome leads to degradation of the LDL into its constituent parts (that is, cholesterol, fatty acids, and amino acids), which are released for reuse by the cell, or are excreted. In this paper, we formulate a mathematical model of LDL endocytosis, consisting of a system of ordinary differential equations. We validate our model against existing in vitro experimental data, and we use it to explore differences in system behavior when a single bolus of extracellular LDL is supplied to cells, compared to when a continuous supply of LDL particles is available. Whereas the former situation is common to in vitro experimental systems, the latter better reflects the in vivo situation. We use asymptotic analysis and numerical simulations to study the longtime behavior of model solutions. The implications of model-derived insights for experimental design are discussed.

ACTH reduces the rise in ApoB-48 levels after fat intake

It has been repeatedly demonstrated that ACTH administration lowers plasma lipid concentrations in man. The present study was designed to test the hypothesis, based on observations of decreased apolipoprotein B (ApoB) synthesis and secretion in vitro, that ACTH administration inhibits the postprandial output of ApoB in man. Therefore, we studied the response to a fat-rich meal supplemented with Vitamin A in eight healthy volunteers, who underwent this test without premedication, after 4 days administration of ACTH, and after 4 days administration of a glucocorticoid (betamethasone). As expected, fasting plasma levels of low-density lipoproteins (LDL)-cholesterot (-25%) and ApoB (-17%) decreased after ACTH, but not after betamethasone administration. Also, the elevation of plasma ApoB-48 in response to fat intake (to twice the basal levels) was markedly reduced after ACTH administration. However, the postprandial rise in plasma triglycerides and retinyl palmitate was unimpaired, suggesting that ACTH administration induced the secretion of fewer but larger chylomicrons. The effect of betamethasone on the postprandial response was similar but less pronounced. This study confirms earlier reports on the lipid-lowering effects of ACTH and supports our theory, based on in vitro studies, that the lipid-lowering effects of ACTH administration in man involves an inhibition of ApoB production. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

Chylomicron particle size and number, factor VII activation and dietary monounsaturated fatty acids

This study evaluated the effects of substituting dietary saturated fatty acids (SFAs) with monounsaturated fatty acids (MUFAs) on postprandial chylomicron (triacylglycerol (TAG), apolipoprotein B-48 (apo B-48) and retinyl ester (RE)), chylomicron particle size and factor VII (FVII) response when subjects were given a standard meal. In a controlled sequential design, 51 healthy young subjects followed an SFA-rich diet (Reference diet) for 8 weeks after which half of the subjects followed a moderate MUFA diet (n = 25) and half followed a high MUFA diet (n = 26) for 16 weeks. Fasting lipoprotein and lipid measurements were evaluated at baseline and at 8-week intervals during the Reference and MUFA diets. In 25 of the subjects (n = 12 moderate MUFA, n = 13 high MUFA), postprandial responses to a standard test meal containing RE and 13 C-tripalmitin were investigated at the end of the Reference and the MUFA diet periods. Although there were no differences in the postprandial lipid markers (TAG, RE, C-13-TAG) on the two diets, the postprandial apo B-48 response (incremental area under the curve (IAUC) was reduced by 21% on the moderate MUFA diet (NS) and by 54% on the high MUFA diet (P < 0.01). The postprandial peak concentrations of apo B-48 were reduced by 33% on the moderate MUFA diet (P < 0.01) and 48% on the high MUFA diet (P < 0.001). Fasting values for factor VII activity (FVIIc), activated factor VII (FVIIa) or factor VII antigen (FVIIag) did not differ significantly when subjects were transferred from Reference to MUFA diets. However, the postprandial increases in coagulation FVII activity (FVIIc) were 18% lower and of activated FVII (FVIIa) were 17% lower on the moderate MUFA diet (NS). Postprandial increases in FVIIc and FVIIa were 50% (P < 0.05) and 29% (P < 0.07) lower on the high MUFA diet and the area under the postprandial FVIIc response curve (AUC) was also lower on the high MUFA diet (P < 0.05). Significantly higher ratios of RE:apo B-48 (P < 0.001) and 13 C-palmitic acid:apo B-48 (P < 0.01) during both MUFA diets suggest that the CMs formed carry larger amounts of dietary lipids per particle, reflecting an adaptation to form larger lipid droplets in the enterocyte when increased amounts of dietary MUFAs are fed. Smaller numbers of larger chylomicrons may explain attenuated activation of factor VII during the postprandial state when the background diet is rich in MUFA. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

Mobilisation of enterocyte fat stores by oral glucose in humans

Background and aims: When a high fat oral load is followed several hours later by further ingestion of nutrients, there is an early postprandial peak in plasma triacylglycerol (TG). The aim of this study was to investigate the location and release of lipid from within the gastrointestinal tract. Methods: Ten healthy patients undergoing oesopho-gastro-duodenoscopy (OGD) were recruited. At t=0, all patients consumed a 50 g fat emulsion and at t=5 hours they consumed either water or a 38 g glucose solution. OGD was performed at t=6 hours and jejunal biopsy samples were evaluated for fat storage. A subgroup of five subjects then underwent a parallel metabolic study in which postprandial lipid and hormone measurements were taken during an identical two meal protocol. Results: Following oral fat at t=0, samples from patients that had subsequently ingested glucose exhibited significantly less staining for lipid within the mucosa and submucosa of the jejunum than was evident in patients that had consumed only water (p=0.028). There was also less lipid storage within the cytoplasm of enterocytes (p=0.005) following oral glucose. During the metabolic study, oral glucose consumed five hours after oral fat resulted in a postprandial peak in plasma TG, chylomicron-TG, and apolipoprotein B48 concentration compared with oral water. Conclusion: After a fat load, fat is retained within the jejunal tissue and released into plasma following glucose ingestion, resulting in a peak in chylomicron-TG which has been implicated in the pathogenesis of atherosclerosis.

Nutrition Society Silver Medal Lecture Nutrigenetics and personalised nutrition: how far have we progressed and are we likely to get there?

Nutrigenetics and personalised nutrition are components of the concept that in the future genotyping will be used as a means of defining dietary recommendations to suit the individual. Over the last two decades there has been an explosion of research in this area, with often conflicting findings reported in the literature. Reviews of the literature in the area of apoE genotype and cardiovascular health, apoA5 genotype and postprandial lipaemia and perilipin and adiposity are used to demonstrate the complexities of genotype-phenotype associations and the aetiology of apparent between-study inconsistencies in the significance and size of effects. Furthermore, genetic research currently often takes a very reductionist approach, examining the interactions between individual genotypes and individual disease biomarkers and how they are modified by isolated dietary components or foods. Each individual possesses potentially hundreds of 'at-risk' gene variants and consumes a highly-complex diet. In order for nutrigenetics to become a useful public health tool, there is a great need to use mathematical and bioinformatic tools to develop strategies to examine the combined impact of multiple gene variants on a range of health outcomes and establish how these associations can be modified using combined dietary strategies.

Noncompetitive plasma biokinetics of deuterium-labeled natural and synthetic alpha-tocopherol in healthy men with an apoE4 genotype

Previous studies comparing the biokinetics of deuterated natural (RRR) and synthetic (all-rac) α-tocopherol (vitamin E) used a simultaneous ingestion or competitive uptake approach and reported relative bioavailability ratios close to 2:1, higher than the accepted biopotency ratio of 1.36:1. The aim of the current study was to compare the biokinetics of deuterated natural and synthetic vitamin E using a noncompetitive uptake model both before and after vitamin E supplementation in a distinct population. Healthy men (n = 10) carrying the apolipoprotein (apo)E4 genotype completed a randomized crossover study, comprised of two 4-wk treatments with 400 mg/d (RRR-α-tocopheryl and all-rac-α-tocopheryl acetate) with a 12-wk washout period between treatments. Before and after each treatment period, the subjects consumed a capsule containing 150 mg deuterated α-tocopheryl acetate in either the PRR or all-rac form depending on their treatment regimen. Blood was obtained up to 48 h after ingestion, and tocopherols analyzed by LC/MS. After deuterated all-rac administration, plasma deuterated tocopherol maximum concentrations and area under the concentration vs. time curves (AUC) were lower than those following RRR administration. The RRR:all-rac ratios determined from the deuterated biokinetic profiles (maximum concentration; C-max) and AUCs were 1.35:1 &PLUSMN; 0.17 and 1.33:1 &PLUSMN; 0.18, respectively. The 4-wk supplementation with either PRR or all-rac significantly increased plasma a-tocopherol concentrations (P < 0.001), but decreased the plasma response to newly absorbed deuterated RRR or all-rac α-tocopherol. Using a noncompetitive uptake approach, the relative bioavailability of natural to synthetic vitamin E in apoE4 males was close to the currently accepted biopotency ratio of 1.36:1.

Differential uptake of subfractions of triglyceride-rich lipoproteins by THP-1 macrophages

It is well known that raised plasma triglycerides (TG) are positively linked to the development of coronary heart disease. However, triglycerides circulate in a range of distinct lipoprotein subtractions and the relative atherogenicity of these subtractions is not clear. In this study, three fractions of triglyceride rich lipoprotein (TRL) were isolated from normolipidaemic males according to their differing Svedberg flotation (S-f) rates: chylomicron (CM, S-f > 400), very low-density lipoprotein (VLDL)-1 (S-f 60-400) and VLDL-2 (S-f 20-60). These fractions were incubated with THP-1 monocyte-derived macrophages for determination of cholesterol and TG accumulation, in the presence and absence of the lipoprotein lipase (LPL) inhibitor orlistat. Expression of LDL receptor related protein (LRP) and apolipoprotein B48 receptor (apoB48R) was also examined in both differentiating monocytes, and monocyte-derived macrophages, incubated with TRL. VLDL-I caused a significantly greater accumulation of TG within macrophages compared to VLDL-2. Binding studies also tended to show a greater preference for VLDL-1. No change in expression of LRP or apoB48R was observed in fully differentiated macrophages incubated with VLDL-1, VLDL-2 or CM, although a greater expression of LRP mRNA was observed in differentiating monocytes exposed to VLDL-1, compared to those incubated with CM or VLDL-2. TG loading in response to all three TRL fractions was blocked by orlistat, suggesting that it is likely that the major pathway for uptake of TG was hydrolysis by LPL. Calculations suggested that direct uptake of particles accounts for between 12 and 25% of total TAG uptake. In conclusion, THP monocyte-derived macrophages demonstrate a preference for VLDL-1, both through the LPL pathway and by direct uptake of whole particles. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

Influence of apoA-V gene variants on postprandial triglyceride metabolism: impact of gender

Although apolipoprotein AN (apoA-V) polymorphisms have been consistently associated with fasting triglyceride (TG) levels, their impact on postprandial lipemia remains relatively unknown. In this study, we investigate the impact of two common apoA-V polymorphisms (-1131 T>C and S19W) and apoA-V haplotypes on fasting and postprandial lipid metabolism in adults in the United Kingdom (n = 259). Compared with the wild-type TT, apoA-V -1131 TC heterozygotes had 15% (P = 0.057) and 21% (P = 0.002) higher fasting TG and postprandial TG area under the curve (AUC), respectively. Significant (P = 0.038) and nearly significant (P = 0.057) gender X genotype interactions were observed for fasting TG and TG AUC, with a greater impact of genotype in males. Lower HDL-cholesterol was associated with the rare TC genotype (P = 0.047). Significant linkage disequilibrium was found between the apoA-V -1131 T>C and the apoC-III 3238 C>G variants, with univariate analysis indicating an impact of this apoC-III single nucleotide polymorphism (SNP) on TG AUC (P = 0.015). However, in linear regression analysis, a significant independent association with TG AUC (P = 0.007) was only evident for the apoA-V -1131 T>C SNP, indicating a greater relative importance of the apoA-V genotype.